|Bid||46.00 x 800|
|Ask||58.86 x 2200|
|Day's Range||46.58 - 48.63|
|52 Week Range||46.58 - 75.75|
|Beta (3Y Monthly)||1.24|
|PE Ratio (TTM)||19.99|
|Earnings Date||Feb 6, 2019 - Feb 11, 2019|
|Forward Dividend & Yield||1.91 (3.81%)|
|1y Target Est||55.79|
NEW YORK, Dec. 18, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Cardinal Health, Inc. (NYSE:CAH) has pleased shareholders over the past 10 years, by paying out dividends. The company is currently worth US$16b, and now yields roughly 3.6%. Does Cardinal Health Read More...
Hedge funds and other investment firms that we track manage billions of dollars of their wealthy clients’ money, and needless to say, they are painstakingly thorough when analyzing where to invest this money, as their own wealth depends on it. Regardless of the various methods used by elite investors like David Tepper and Dan Loeb, […]
Cardinal (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DUBLIN, Ohio, Dec. 7, 2018 /PRNewswire/ -- Cardinal Health (CAH) today announced that its board of directors has elected J. Michael Losh as an independent director effective December 5. Losh will serve as the chairman of the Audit Committee.
DUBLIN, Ohio, Nov. 30, 2018 /PRNewswire/ -- Oncologists are growing more confident in their ability to meet the requirements of the Medicare Access & CHIP Reauthorization Act (MACRA), according to new research from Cardinal Health Specialty Solutions. Request a copy of the Oncology Insights report at www.cardinalhealth.com/oncologyinsights. The report compares current views about MACRA to responses collected in early 2017, shortly after MACRA went into effect.
Cardinal Health introduces approach to address sustainable cost control DUBLIN, Ohio , Nov. 27, 2018 /PRNewswire/ -- At the 2018 American Society of Health System Pharmacists (ASHP) Midyear Clinical Meeting, ...
The drug distributor is able to turn its significant size and market share into key competitive advantages. Cardinal is an important cog in the pharmaceutical industry, as many supply-chain participants depend on its services for streamlined product distribution and procurement. Cardinal is the third-largest pharmaceutical distributor by revenue and is the main supplier to CVS Health's retail pharmacy network.
Based on Cardinal Health Inc’s (NYSE:CAH) earnings update on 30 September 2018, analysts seem highly optimistic, with earnings expected to grow by a high double-digit of 83% in the upcoming Read More...
Cardinal Health Inc. is putting federal tax savings and proceeds of a partial divestiture into more share buybacks and capital investments, while continuing cost-cutting measures.
The CAH chart, below, shows the stock price had been in a consistent downtrend from January of this year, making a series of lower lows and lower highs. The market selloff in October resulted in CAH successfully testing its $50.00 support level. Given that CAH had previously violated its downtrend, based for approximately six months and has now violated long-standing resistance with respectable volume, we believe it has formed a bullish reversal pattern.
Cardinal Health posted a more than fivefold surge in first-quarter profit, led by growth in its pharmaceuticals business despite generic drug competition pressures.
Shares of Cardinal Health Inc. rallied 2.9% in premarket trade Thursday after the healthcare services company reported fiscal first-quarter profit and revenue that rose above expectations, boosted by strength in its pharmaceuticals business. Net income rose to $593 million, or $1.94 a share, from $115 million, or 36 cents a share, in the same period a year ago, with the naviHealth divestiture resulting in a gain of $503 million. Excluding non-recurring items, adjusted earnings per share came to $1.29, above the FactSet consensus of $1.08. Revenue increased 8% to $35.2 billion, beating the FactSet consensus of $33.7 billion. Pharmaceutical segment revenue grew 9% to $31.4 billion, well above the FactSet consensus of $29.8 billion. The company affirmed its 2019 adjusted EPS outlook of $4.90 to $5.15, which surrounds the FactSet consensus of $4.99. The stock has rallied 9.6% over the past three months through Wednesday, while the SPDR Health Care Select Sector ETF has gained 3.4% and the S&P 500 has slipped 1.5%.